Clinical Trial Search

Primary: Mean Change From Baseline Psoriasis Area and Severity Index (PASI) at Week-24 After Treatment With Guselkumab. — 61.8 percent change from baseline PASI

Primary: Ratio of Trans-epidermal Water Loss (TEWL) at 16 Weeks After Use — 1.69 ratio — p=<0.05

Primary: PAP Adherence — 32.9; 25.67 Number of nights — p=0.2313

Primary: Cohorts 1a and 1b: Number of Participants With Solicited Local (Injection Site) Adverse Events (AEs) for 7 Days After Vaccination 1 in the Primary Regimen — 50; 50; 57…

Primary: Pain and Function Goal-setting — 0.0081; 0.0016; 0.0364; 0.0283 Proportion of patient visits — p=<0.05

Primary: Percentage of Participants Who Were Alive and Have None of the 6 Major Functional Disabilities (MFDs) at Month 24 — 85.7 Percentage of participants

Primary: Number of Participants With a Positive bHCG Level as Detected by a Blood Test — 19; 19 Participants

Primary: Number of Participants With Dose-Limiting Toxicity (DLT) in Phase 1 — 0; 1; 1; 3 Participants

Primary: Intraoperative and Postoperative Opioid Consumption — 191; 139.4 MME/day

Primary: Mean Cortisol (CRT) During Trier Social Stress Test (TSST) — 19.17; 16.87; 15.71; 13.89 pg/mL — p=0.37

Primary: Percentage of Participants With Solicited Injection-site Adverse Events (AEs) Following Vaccination With Separate V116 Lots — 13.4; 14.2; 13.1; 72.9 Percentage of…

Primary: Depressive Symptoms — 7.01; 6.61; 4.96; 6.39 score on a scale

Primary: Pharmacokinetics (PK): Maximum Concentration (Cmax) of Dabigatran — 192; 276 nanogram per milliliter (ng/mL)

Primary: Change From Baseline to Week 16 in the Percentage of Time in Range [70 to 180 Milligram Per Deciliter (mg/dL)] — 26.22 percentage of time

Primary: Absolute Change in Intrahepatic Lipid Content, by 1H-MRS — -6.6; 3.6 Mean absolute percentage change